Adaptive Biotechnologies (ADPT) Non-Current Assets (2018 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Assets across 9 years of filings, most recently posting $214.1 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $214.1 million, down 15.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $870.6 million (down 12.36% YoY), and the FY2025 annual result was $212.6 million, down 16.85% from the prior year.
• Non-Current Assets came in at $214.1 million for Q1 2026 at Adaptive Biotechnologies, up from $212.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $439.1 million in Q1 2022 to a low of $209.2 million in Q3 2025.
• The 5-year median for Non-Current Assets is $254.4 million (2025), against an average of $273.1 million.
• Peak annual rise in Non-Current Assets reached 42.96% in 2022, while the deepest fall reached 43.44% in 2022.
• Adaptive Biotechnologies' Non-Current Assets stood at $294.5 million in 2022, then slipped by 14.78% to $250.9 million in 2023, then rose by 1.86% to $255.6 million in 2024, then slipped by 16.85% to $212.6 million in 2025, then grew by 0.75% to $214.1 million in 2026.
• The last three Non-Current Assets figures came in at $214.1 million (Q1 2026), $212.6 million (Q4 2025), and $209.2 million (Q3 2025), per Business Quant data.